GlassScriptPhysician profile
David A Cohen
NPI 1215908645
$13,933.65
in general payments reported to CMS, 2019-2025
27 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $33.23 · 2021: $405 · 2022: $774 · 2023: $989 · 2024: $198 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11,204.39 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $532.80 | 2019-2025 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $413.37 | 2023-2025 | Inspire |
| Pfizer INC. | $261.13 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $173.77 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $159.16 | 2019-2024 | Breztri |
| Organogenesis INC. | $131.25 | 2021 | |
| Abbvie INC. | $117.11 | 2019-2023 | Vraylar |
| Esperion Therapeutics, INC. | $116.21 | 2022 | |
| Amgen INC. | $113.20 | 2020-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $107.96 | 2019-2022 | |
| Lilly USA, LLC | $85.58 | 2022-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.20 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $75.24 | 2019-2023 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $60.21 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $43.21 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $41.69 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $39.50 | 2023 | Proclaim |
| Daiichi Sankyo INC. | $30.02 | 2019 | |
| Merck Sharp & Dohme LLC | $26.49 | 2019-2022 | |
| Merz North America, INC. | $24.81 | 2021 | |
| Philips North America LLC | $19.82 | 2022 | |
| Medtronic, INC. | $19.70 | 2022 | |
| Bausch Health US, LLC | $19.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.82 | 2021 | |
| Almatica Pharma LLC | $14.14 | 2024 | Loreev Xr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.